Skip to content
Lumiracoxib
Lumiracoxib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against prostaglandin G/H synthase 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AH: Coxibs
— M01AH06: Lumiracoxib
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoarthritisD010003EFO_0002506M15-M19——62—8
PainD010146EFO_0003843R52———2—2
Healthy volunteers/patients————1—1
Controlled hypotensionD007023———1—1
Musculoskeletal painD059352———1—1
Gouty arthritisD015210———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Knee osteoarthritisD020370EFO_0004616M17——2——2
Hip osteoarthritisD015207EFO_1000786M16——1——1
Rheumatoid arthritisD001172EFO_0000685M06.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6—1———1
ArthralgiaD018771HP_0002829M25.5—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLUMIRACOXIB
INNlumiracoxib
Description
Lumiracoxib is an amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. It has a role as a cyclooxygenase 2 inhibitor and a non-steroidal anti-inflammatory drug. It is an organofluorine compound, an organochlorine compound, an amino acid, a secondary amino compound and a monocarboxylic acid.
Classification
Small molecule
Drug classcyclooxygenase-2 inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1
Identifiers
PDB4OTY
CAS-ID220991-20-8
RxCUI—
ChEMBL IDCHEMBL404108
ChEBI ID73044
PubChem CID151166
DrugBankDB01283
UNII IDV91T9204HU (ChemIDplus, GSRS)
Target
Agency Approved
PTGS2
PTGS2
Organism
Homo sapiens
Gene name
PTGS2
Gene synonyms
COX2
NCBI Gene ID
5743
Protein name
prostaglandin G/H synthase 2
Protein synonyms
COX-2, cyclooxygenase 2, cyclooxygenase 2b, Cyclooxygenase-2, PGH synthase 2, PGHS-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
Uniprot ID
Q16876
Mouse ortholog
Ptgs2 (19225)
prostaglandin G/H synthase 2 (Q543K3)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 930 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details